Annual EBITDA
-$34.58 M
+$5.39 M+13.49%
December 31, 2023
Summary
- As of February 8, 2025, ITRM annual EBITDA is -$34.58 million, with the most recent change of +$5.39 million (+13.49%) on December 31, 2023.
- During the last 3 years, ITRM annual EBITDA has risen by +$1.43 million (+3.96%).
- ITRM annual EBITDA is now -159.01% below its all-time high of -$13.35 million, reached on December 31, 2016.
Performance
ITRM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$5.36 M
-$973.00 K-22.18%
September 30, 2024
Summary
- As of February 8, 2025, ITRM quarterly EBITDA is -$5.36 million, with the most recent change of -$973.00 thousand (-22.18%) on September 30, 2024.
- Over the past year, ITRM quarterly EBITDA has stayed the same.
- ITRM quarterly EBITDA is now -159.00% below its all-time high of $9.09 million, reached on June 30, 2021.
Performance
ITRM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$27.68 M
-$2.38 M-9.41%
September 30, 2024
Summary
- As of February 8, 2025, ITRM TTM EBITDA is -$27.68 million, with the most recent change of -$2.38 million (-9.41%) on September 30, 2024.
- Over the past year, ITRM TTM EBITDA has stayed the same.
- ITRM TTM EBITDA is now -349.47% below its all-time high of $11.10 million, reached on March 31, 2022.
Performance
ITRM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ITRM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.5% | 0.0% | 0.0% |
| 3 y3 years | +4.0% | 0.0% | 0.0% |
| 5 y5 years | +54.5% | 0.0% | 0.0% |
ITRM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +58.4% | -265.6% | +81.3% | -349.5% | +66.7% |
| 5 y | 5-year | at high | +66.0% | -159.0% | +94.4% | -349.5% | +76.7% |
| alltime | all time | -159.0% | +66.0% | -159.0% | +94.4% | -349.5% | +76.7% |
Iterum Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$5.36 M(+22.2%) | -$27.68 M(+9.4%) |
| Jun 2024 | - | -$4.39 M(-33.1%) | -$25.30 M(-21.4%) |
| Mar 2024 | - | -$6.56 M(-42.3%) | -$32.21 M(-6.9%) |
| Dec 2023 | -$34.58 M(-13.5%) | -$11.38 M(+281.7%) | -$34.58 M(+24.2%) |
| Sep 2023 | - | -$2.98 M(-73.6%) | -$27.84 M(-47.9%) |
| Jun 2023 | - | -$11.29 M(+26.5%) | -$53.45 M(+12.9%) |
| Mar 2023 | - | -$8.93 M(+92.9%) | -$47.33 M(+18.4%) |
| Dec 2022 | -$39.97 M(-52.0%) | -$4.63 M(-83.8%) | -$39.97 M(+8.6%) |
| Sep 2022 | - | -$28.59 M(+453.0%) | -$36.81 M(+1064.8%) |
| Jun 2022 | - | -$5.17 M(+228.1%) | -$3.16 M(-128.5%) |
| Mar 2022 | - | -$1.58 M(+7.5%) | $11.10 M(-113.3%) |
| Dec 2021 | -$83.20 M(+131.1%) | -$1.47 M(-129.0%) | -$83.20 M(-6.1%) |
| Sep 2021 | - | $5.05 M(-44.4%) | -$88.62 M(-12.5%) |
| Jun 2021 | - | $9.09 M(-109.5%) | -$101.22 M(-14.6%) |
| Mar 2021 | - | -$95.87 M(+1293.5%) | -$118.53 M(+229.2%) |
| Dec 2020 | -$36.01 M | -$6.88 M(-8.9%) | -$36.01 M(-31.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$7.55 M(-8.2%) | -$52.27 M(-30.9%) |
| Jun 2020 | - | -$8.23 M(-38.3%) | -$75.63 M(-20.1%) |
| Mar 2020 | - | -$13.34 M(-42.4%) | -$94.71 M(-6.8%) |
| Dec 2019 | -$101.67 M(+33.7%) | -$23.15 M(-25.1%) | -$101.67 M(-0.5%) |
| Sep 2019 | - | -$30.91 M(+13.2%) | -$102.21 M(+6.6%) |
| Jun 2019 | - | -$27.31 M(+34.5%) | -$95.92 M(+13.9%) |
| Mar 2019 | - | -$20.31 M(-14.3%) | -$84.19 M(+10.7%) |
| Dec 2018 | -$76.02 M(+158.7%) | -$23.69 M(-3.8%) | -$76.05 M(+23.6%) |
| Sep 2018 | - | -$24.62 M(+58.1%) | -$61.54 M(+36.2%) |
| Jun 2018 | - | -$15.57 M(+27.9%) | -$45.19 M(+25.5%) |
| Mar 2018 | - | -$12.17 M(+32.7%) | -$36.02 M(+22.3%) |
| Dec 2017 | -$29.39 M(+120.1%) | -$9.18 M(+10.9%) | -$29.46 M(+45.2%) |
| Sep 2017 | - | -$8.27 M(+29.3%) | -$20.28 M(+68.9%) |
| Jun 2017 | - | -$6.40 M(+14.1%) | -$12.01 M(+114.1%) |
| Mar 2017 | - | -$5.61 M | -$5.61 M |
| Dec 2016 | -$13.35 M | - | - |
FAQ
- What is Iterum Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Iterum Therapeutics?
- What is Iterum Therapeutics annual EBITDA year-on-year change?
- What is Iterum Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Iterum Therapeutics?
- What is Iterum Therapeutics quarterly EBITDA year-on-year change?
- What is Iterum Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Iterum Therapeutics?
- What is Iterum Therapeutics TTM EBITDA year-on-year change?
What is Iterum Therapeutics annual EBITDA?
The current annual EBITDA of ITRM is -$34.58 M
What is the all time high annual EBITDA for Iterum Therapeutics?
Iterum Therapeutics all-time high annual EBITDA is -$13.35 M
What is Iterum Therapeutics annual EBITDA year-on-year change?
Over the past year, ITRM annual EBITDA has changed by +$5.39 M (+13.49%)
What is Iterum Therapeutics quarterly EBITDA?
The current quarterly EBITDA of ITRM is -$5.36 M
What is the all time high quarterly EBITDA for Iterum Therapeutics?
Iterum Therapeutics all-time high quarterly EBITDA is $9.09 M
What is Iterum Therapeutics quarterly EBITDA year-on-year change?
Over the past year, ITRM quarterly EBITDA has changed by $0.00 (0.00%)
What is Iterum Therapeutics TTM EBITDA?
The current TTM EBITDA of ITRM is -$27.68 M
What is the all time high TTM EBITDA for Iterum Therapeutics?
Iterum Therapeutics all-time high TTM EBITDA is $11.10 M
What is Iterum Therapeutics TTM EBITDA year-on-year change?
Over the past year, ITRM TTM EBITDA has changed by $0.00 (0.00%)